Agile Therapeutics Acknowledges New Government Guidance Reinforcing Requirement to Cover Contraceptives that a Woman and Her Heathcare Provider Determine are Medically Appropriate at No Cost
12 janv. 2022 17h29 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- On January 10, 2022, the tri-agencies, Department of Labor (DOL), Health and Human Services (HHS) and Treasury issued new guidance that supports...
Agile Therapeutics and Afaxys Partner to Expand Access to Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System
10 janv. 2022 08h01 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J. and CHARLESTON, S.C., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced a new alliance with Afaxys Pharma, LLC...
Agile Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
05 janv. 2022 08h03 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will...
Agile Therapeutics to Present at the Biotech Showcase and H.C. Wainwright BioConnect Virtual Conferences
05 janv. 2022 08h01 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will...
Agile Therapeutics Reports Third Quarter 2021 Financial Results
02 nov. 2021 16h05 HE
|
Agile Therapeutics, Inc.
Prescription Demand Growth Continues in the Third Quarter 2021 with a 61% Increase in Twirla Cycles Dispensed Twirla Refill Rates Continue to Grow by 86% in Third Quarter 2021 ...
Agile Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on Tuesday, November 2, 2021
22 oct. 2021 08h01 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report third quarter 2021 financial results after...
Agile Therapeutics Applauds Congressional Chairs’ Letter to Biden Administration Requesting Enforcement of Contraceptive Access Under Affordable Care Act
12 oct. 2021 08h01 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today applauded House Congressional Committee leaders in urging...
Agile Therapeutics Appoints Josephine Torrente to its Board of Directors
08 oct. 2021 16h05 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Josephine Torrente has been appointed to the Company’s...
Agile Therapeutics Announces Pricing of $22,666,650 Underwritten Public Offering of Common Stock and Warrants
08 oct. 2021 08h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of...
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Warrants
07 oct. 2021 16h05 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock...